VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased to announce the presentation of its research on novel small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes at the 36th EORTC-NCI-AARC Symposium in Barcelona, Spain, on October 25, 2024.

Rakovina’s novel class of bifunctional small molecule compounds, known as kt-3000 series, has demonstrated potent dual inhibition of PARP1/2 and HDAC enzymes in preclinical studies. Compared to single-function inhibitors such as olaparib (PARP) and vorinostat (HDAC), dual-function kt-3000 compounds demonstrate greater potency against both HR-deficient and proficient cancer cells.

Based on these results, the Company intends to explore formulations of the lead compound, kt-3283, to support potential advancement to human clinical trials, while continuing to further medicinal chemistry efforts that refine properties of the class.

“The kt-3000 series represents a significant advancement toward overcoming treatment resistance to first-generation PARP-inhibitors. These bifunctional PARP+HDAC inhibitors could enable us to effectively address resistance in various cancers while minimizing toxicity associated with traditional combination therapies,” said Rakovina Therapeutics Executive Chairman Jeffrey Bacha.

“We are excited to present our findings at the symposium and to continue advancing these promising compounds toward clinical development,” he added.

Presentation Details:

Title: Small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes
Presentation Date: October 25, 2024
Abstract Number: 338

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition.

Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.

For Further Information, Contact:
Jeffrey Bacha, BSC, MBA
Executive Chairman and Director
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations and Media:
Ira M. Gostin
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
775-391-0213